What is Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (603567.SS) StockRank?

MoatMap's StockRank for Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) is 26/100, with a Sell signal. This is a composite score combining Quality (33), Value (57), and Momentum (27) factor ranks across MoatMap's 20,000+ stock universe.

Does Heilongjiang ZBD Pharmaceutical Co., Ltd. have an economic moat?

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Heilongjiang ZBD Pharmaceutical Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) is Sell, based on a StockRank of 26/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Heilongjiang ZBD Pharmaceutical Co., Ltd. in?

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

603567.SS

SELLREMOVE

Heilongjiang ZBD Pharmaceutical Co., Ltd. · Healthcare · China · $994M · Avg Vol: $14M/d

StockRank

P/E (TTM)

—

ROE

-22.4%

D/E

0.5x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Heilongjiang ZBD Pharmaceutical is a small-cap domestic pharma player with low quality metrics (Q: 33). It lacks the global scale, regulatory moats, and high-utilization capacity required to benefit from the CDMO pricing power cycle.

COMPANY DESCRIPTION

Heilongjiang ZBD Pharmaceutical specializes in the development, production, and sale of Traditional Chinese Medicine (TCM) injections and oral formulations, with a core focus on cardiovascular and cerebrovascular diseases. The company's competitive moat is anchored by its flagship product, Shuxuening Injection, and its extensive hospital distribution network across China. It is a prominent regional player in the therapeutic TCM market, navigating regulatory shifts through product diversification.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	624M	465M	400M	118M	-42.6%
EPS	0.03	0.07	0.07	-0.21	53.8%
Shares	942M	942M	941M	941M	-0.1%
Debt	432M	466M	487M	461M	2.1%
Equity	1.0B	1.1B	1.2B	928M	-4.0%
Op CF	-48M	-71M	24M	48M	96.0%
Inv CF	42M	26M	-16M	-88M	—
Fin CF	-62M	113M	-67M	-103M	—

PRICE (1M)-24.5%

SMA 50SMA 200

$0.80

RSI (14)

16.2

52W High

$1.97

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

-22.7%26.8

ROE

-22.4%28.8

GP/Assets

-7.0%7.3

Op. Margin

-45.8%21.5

FCF/Assets

9.9%86.8

Piotroski

—55.7

Int. Cover

-10.7x23.8

D/E Ratio

0.51x31.0

Current Ratio

1.38x21.4

Value

P/E (TTM)

—N/A

EV/EBITDA

-7.0x77.2

P/FCF

43.6x92.8

P/B

0.9x80.9

P/S

10.9x24.5

Div Yield

—N/A

Momentum

52W High %

41%13.3

RS 6M

-54%19.9

SMA 50/200

0.75x7.6

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+164%84.3

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$994M

P/E (Forward)

5.3x

Gross Margin

-145.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 603567.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
603567.SS	Heilongjiang ZBD Pharmaceutical Co., Ltd.(you)	$994M	26	SELL
300702.SZ	Zhejiang Tianyu Pharmaceutical Co., Ltd.	$989M	26	SELL
002940.SZ	Zhejiang AngLiKang Pharmaceutical CO.,LTD.	$1.0B	25	SELL
688621.SS	Beijing Sun-Novo Pharmaceutical Research Co., Ltd.	$894M	26	SELL
600422.SS	KPC Pharmaceuticals,Inc.	$999M	24	SELL
600252.SS	Guangxi Wuzhou Zhongheng Group Co., Ltd	$1.0B	29	SELL
300363.SZ	Porton Pharma Solutions Ltd.	$1.2B	26	SELL
002038.SZ	Beijing SL Pharmaceutical Co., Ltd.	$893M	28	SELL
688176.SS	Jiangsu Yahong Meditech Co., Ltd.	$961M	30	SELL
002907.SZ	Chongqing Pharscin Pharmaceutical Co., Ltd.	$765M	26	SELL

Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.1%

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) — Stock Score Summary

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) has a MoatMap StockRank of 26/100 based on Quality (33/100), Value (57/100), and Momentum (27/100) factor scores. The current signal is SELL. Heilongjiang ZBD Pharmaceutical is a small-cap domestic pharma player with low quality metrics (Q: 33). It lacks the global scale, regulatory moats, and high-utilization capacity required to benefit from the CDMO pricing power cycle.

Key Financial Metrics

Price	$0.80
Market Cap	$994M
P/E (Forward)	5.34
Price/Book	0.92
Return on Equity	-22.4%
Return on Invested Capital	-22.7%
Debt/Equity	51.28
Gross Margin	-145.9%
Operating Margin	-45.8%
Revenue Growth	-61.3%
Free Cash Flow	$23M

Heilongjiang ZBD Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Heilongjiang ZBD Pharmaceutical Co., Ltd.’s (603567.SS) StockRank?: MoatMap’s StockRank for Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) is 26/100, with a Sell signal. It is a composite of Quality (33), Value (57), and Momentum (27) factor ranks across MoatMap’s 20,000+ stock universe.
Does Heilongjiang ZBD Pharmaceutical Co., Ltd. have an economic moat?: Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Heilongjiang ZBD Pharmaceutical Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) is Sell, based on a StockRank of 26/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Heilongjiang ZBD Pharmaceutical Co., Ltd. in?: Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).